Target Name: LHCGR
NCBI ID: G3973
Review Report on LHCGR Target / Biomarker Content of Review Report on LHCGR Target / Biomarker
LHCGR
Other Name(s): LHRHR | Hypergonadotropic hypogonadism | Lutropin-choriogonadotropic hormone receptor | LHR | LSHR_HUMAN | LGR2 | Luteinizing hormone/choriogonadotropin receptor | LH/CG-R | luteinizing hormone/choriogonadotropin receptor | LCGR | hypergonadotropic hypogonadism | ULG5 | LH/CGR | HHG | Luteinizing hormone (LH) receptor (LHR) | Luteinizing hormone receptor | FLJ41504 | lutropin/choriogonadotropin receptor | Lutropin/choriogonadotropin receptor | LSH-R

Discovering The Higgs Boson At The LHC

The Large Hadron Collider (LHC) is one of the most significant scientific instruments in the field of particle physics. It is a particle accelerator that is used to collide protons at very high energies in order to study the fundamental nature of the universe. The LHC is part of the ATLAS experiment, which is one of the four large-scale particle physics experiments being conducted by the European Organization for Nuclear Research (CERN).

The LHC is a powerful tool for studying the Higgs boson, a particle that is predicted by the Standard Model of particle physics and has been observed using the LHC. The Higgs boson is thought to have a mass of around 125 amu (about 1.25 x 10 ^-23 kilograms) and is considered to be the last remaining piece of the so-called \"Technicolor\" theory.

In addition to studying the Higgs boson, the LHC is also used to study a variety of other particles and phenomena. For example, it is used to study the fundamental forces of nature, such as gravity and electromagnetism. structure of the universe and the fundamental particles that make up everything from the smallest to the largest scales.

One of the main challenges of the LHC is its size and complexity. It is a large machine that requires a significant amount of funding and resources to operate. It is also a powerful tool that can generate a large amount of data, which can be difficult to process and analyze.

Despite these challenges, the LHC has made some significant discoveries in the field of particle physics. One of the most significant was the discovery of the Higgs boson in 2012. This discovery was the result of a collaboration between the ATLAS experiment and other scientific institutions. It was the first time that a particle with the predicted mass of the Higgs boson had been observed.

In addition to the Higgs boson, the LHC has also discovered a variety of other particles and phenomena. For example, it has observed the top quark, which is one of the four fundamental particles in the Standard Model of particle physics. the Higgs boson in the H decay (H decay) mode, which is a process in which a boson decays into three other particles.

The LHC is an incredibly powerful tool for studying the fundamental nature of the universe. Its ability to generate high-energy particles and its large sample size have made it an important part of the field of particle physics. The LHC has also made some significant discoveries in the field of Higgs boson physics, which is the study of the Higgs boson and its properties.

Protein Name: Luteinizing Hormone/choriogonadotropin Receptor

Functions: Receptor for lutropin-choriogonadotropic hormone (PubMed:11847099). The activity of this receptor is mediated by G proteins which activate adenylate cyclase (PubMed:11847099)

The "LHCGR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LHCGR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LHFPL1 | LHFPL2 | LHFPL3 | LHFPL3-AS1 | LHFPL3-AS2 | LHFPL4 | LHFPL5 | LHFPL6 | LHFPL7 | LHPP | LHX1 | LHX2 | LHX3 | LHX4 | LHX4-AS1 | LHX5 | LHX6 | LHX8 | LHX9 | LIAS | LIF | LIFR | LIFR-AS1 | LIG1 | LIG3 | LIG4 | LILRA1 | LILRA2 | LILRA3 | LILRA4 | LILRA5 | LILRA6 | LILRB1 | LILRB2 | LILRB3 | LILRB4 | LILRB5 | LILRP1 | LILRP2 | LIM domain kinase (LIMK) | LIM2 | LIMA1 | LIMASI | LIMCH1 | LIMD1 | LIMD1-AS1 | LIMD2 | LIME1 | LIMK1 | LIMK2 | LIMS1 | LIMS2 | LIMS3 | LIMS3-LOC440895 | LIMS4 | LIN28A | LIN28B | LIN28B-AS1 | LIN37 | LIN52 | LIN54 | LIN7A | LIN7B | LIN7C | LIN9 | LINC-PINT | LINC-ROR | LINC00028 | LINC00029 | LINC00032 | LINC00051 | LINC00052 | LINC00092 | LINC00102 | LINC00106 | LINC00111 | LINC00112 | LINC00113 | LINC00114 | LINC00115 | LINC00158 | LINC00159 | LINC00160 | LINC00161 | LINC00163 | LINC00173 | LINC00174 | LINC00184 | LINC00189 | LINC00200 | LINC00205 | LINC00207 | LINC00208 | LINC00210 | LINC00221 | LINC00222 | LINC00226 | LINC00235 | LINC00239 | LINC00240